Belite Bio Inc ADR - Asset Resilience Ratio

Latest as of December 2025: 17.87%

Belite Bio Inc ADR (BLTE) has an Asset Resilience Ratio of 17.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Belite Bio Inc ADR (BLTE) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$139.49 Million

Cash + Short-term Investments

Total Assets

$780.56 Million

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how Belite Bio Inc ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Belite Bio Inc ADR.

Liquid Assets Composition Over Time

This chart breaks down Belite Bio Inc ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Belite Bio Inc ADR strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$139.49 Million	17.87%
Total Liquid Assets	$139.49 Million	17.87%

Asset Resilience Insights

Good Liquidity Position: Belite Bio Inc ADR maintains a healthy 17.87% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Belite Bio Inc ADR Industry Peers by Asset Resilience Ratio

Compare Belite Bio Inc ADR's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Belite Bio Inc ADR (2023–2025)

The table below shows the annual Asset Resilience Ratio data for Belite Bio Inc ADR.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	17.87%	$139.49 Million	$780.56 Million	-56.72pp
2024-12-31	74.59%	$113.47 Million	$152.13 Million	--
2023-12-31	0.00%	$0.00	$94.64 Million	--

pp = percentage points

About Belite Bio Inc ADR

NASDAQ:BLTE USA Biotechnology

Market Cap

$6.17 Billion

Market Cap Rank

#3122 Global

#1099 in USA

Share Price

$164.45

Change (1 day)

-1.77%

52-Week Range

$56.81 - $190.30

All Time High

$190.30